NEW YORK (GenomeWeb) – Researchers from Mirna Therapeutics this month published new animal data demonstrating the potential of combining two tumor-suppressing microRNA mimics for the treatment of non-small cell lung cancer (NSCLC).
Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.
Marina Biotech and Mirna Therapeutics this week announced that they have amended an existing licensing agreement to give Mirna greater access to Marina's Smarticle liposomal delivery technology for use with microRNA-based therapeutics.
Mirna Therapeutics has named Sinil Kim as its chief medical officer.
In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.
Three months after releasing preclinical data on its microRNA replacement cancer therapy MRX34, Mirna Therapeutics has begun recruiting patients in a phase I trial of the drug, a company official said this week.